Immunocore Holdings plc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 6YG.MU | IMTX | IOVA | 1541.HK | IDYA | 8SJ.F | |
|---|---|---|---|---|---|---|
| Market cap | 1.35B | 1.05B | 3.94B | 1.23B | 3.12B | 1.84B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | -3.4 | -44.4 | -5.4 | -7.9 | — |
| Price/book | 3.6 | 2.1 | 5.4 | 1.7 | 2.9 | 2.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −6.85% | −20.86% | +387.85% | −66.97% | +5.63% | −37.59% |
| Today | +1.52% | −2.33% | −1.47% | +0.17% | +3.29% | +1.70% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 6YG.MU news ›Analysts Conflicted on These Healthcare Names: Solventum Corporation (SOLV), HCA Healthcare (HCA) and Immunocore Holdings (IMCR)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Solventum Corporation (SOLV), HCA Healthcare (HCA) and Immunocore Holdings (IMCR). In a report released yesterday, Travis Steed from Bank of…
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
Clinical data for first combination of two T cell engagers in a solid tumor will be presented in a poster on Friday, Novem
Analyzing Immunocore (NASDAQ:IMCR) & Vericel (NASDAQ:VCEL)
Posted by Defense World Staff on Oct 24th, 2026 Immunocore (NASDAQ:IMCR – Get Free Report) and Vericel (NASDAQ:VCEL – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based…
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
Profusa Receives ISO 13485:2016 Certificate from GMED Immunocore (IMCR) has dosed the first patient in a Phase 1 trial of IMC-S118AI, its first autoimmune disease candidate. Immunocore announces first patient dosed in the Phase 1 trial of…
Immunocore: FMR reports 3.6% stake in amendment
One passive holder reports sole voting power over 1.73 million Immunocore (IMCR) shares. Stock Titan - [SCHEDULE 13G/A] Immunocore Holdings plc Amended Passive Investment Disclosure Immunocore: FMR reports 3.6% stake in amendment The…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- defenseworld.net1
- stocktitan.net1
- theglobeandmail.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.